Vaccines against cancer and improved transport of active substances into tumor cells - the Canadian biotech company Defence Therapeutics promises no less with its patented technology. In the next six months, Defence Therapeutics intends to prove that its vaccines are safe in Phase 1 trials. That finding could be a liberating blow for the company. Read our research to find out what else makes the biotech tick and why the stock is entering an exciting phase.Den vollständigen Artikel lesen ...
© 2021 researchanalyst.com (EN)